Recent advances in developing targeted protein degraders

被引:0
作者
Cheng, Binbin [1 ,2 ]
Li, Hongqiao [3 ]
Peng, Xiaopeng [4 ]
Chen, Jianjun [5 ]
Shao, Chuxiao [2 ]
Kong, Zhihua [6 ]
机构
[1] Hubei Polytech Univ, Hubei Key Lab Kidney Dis Pathogenesis & Intervent, Huangshi 435003, Peoples R China
[2] Wenzhou Med Univ, Lishui Peoples Hosp, Cent Lab, Lishui Hosp, Lishui 323000, Zhejiang, Peoples R China
[3] Cent Hosp Huangshi, Huangshi 435000, Peoples R China
[4] Gannan Med Univ, Coll Pharm, Ganzhou 314000, Peoples R China
[5] Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, NMPA Key Lab Res & Evaluat Drug Metab, Guangzhou 510515, Peoples R China
[6] Guangdong Prov Hosp, Integrated Tradit Chinese & Western Med, Foshan 528200, Peoples R China
基金
中国国家自然科学基金;
关键词
Targeted protein degradation; Small molecule ligands; PROTACs; Molecular glues; LYTACs; HyTTD; ANTIBODY-BASED PROTACS; MDM2; INHIBITORS; CANCER-THERAPY; DEGRADATION; DISCOVERY; LIGASE; ASGPR; POTENT;
D O I
10.1016/j.ejmech.2024.117212
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Targeted protein degradation (TPD) represents a promising therapeutic approach, encompassing several innovative strategies, including but not limited to proteolysis targeting chimeras (PROTACs), molecular glues, hydrophobic tag tethering degraders (HyTTD), and lysosome-targeted chimeras (LYTACs). Central to TPD are small molecule ligands, which play a critical role in mediating the degradation of target proteins. This review summarizes the current landscape of small molecule ligands for TPD molecules. These small molecule ligands can utilize the proteasome, lysosome, autophagy, or hydrophobic-tagging system to achieve the degradation of target proteins. The article mainly focuses on introducing their design principles, application advantages, and potential limitations. A brief discussion on the development prospects and future directions of TPD technology was also provided.
引用
收藏
页数:19
相关论文
共 50 条
  • [1] Recent advances in targeted protein degraders as potential therapeutic agents
    Yang, Na
    Kong, Bo
    Zhu, Zhaohong
    Huang, Fei
    Zhang, Liliang
    Lu, Tao
    Chen, Yadong
    Zhang, Yanmin
    Jiang, Yulei
    MOLECULAR DIVERSITY, 2024, 28 (01) : 309 - 333
  • [2] Recent advances in targeted protein degraders as potential therapeutic agents
    Na Yang
    Bo Kong
    Zhaohong Zhu
    Fei Huang
    Liliang Zhang
    Tao Lu
    Yadong Chen
    Yanmin Zhang
    Yulei Jiang
    Molecular Diversity, 2024, 28 : 309 - 333
  • [3] Recent advances in developing degraders & inhibitors of lysine methyltransferases
    Velez, Julia
    Kaniskan, H. Umit
    Jin, Jian
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2023, 76
  • [4] Clinical Translation of Targeted Protein Degraders
    Kong, Nikki R.
    Jones, Lyn H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 114 (03) : 558 - 568
  • [5] Natural Product-Inspired Targeted Protein Degraders: Advances and Perspectives
    Li, Jiao
    Cai, Zhenyu
    Li, Xu-Wen
    Zhuang, Chunlin
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (20) : 13533 - 13560
  • [6] TransTACs: Transforming antibodies into targeted protein degraders
    Guo, Yu
    Che, Jinxin
    Dong, Xiaowu
    ACTA PHARMACEUTICA SINICA B, 2025, 15 (02) : 1186 - 1188
  • [7] Recent advances in the development of EGFR degraders: PROTACs and LYTACs
    Hong, Dawei
    Zhou, Bizhong
    Zhang, Bei
    Ren, Hao
    Zhu, Liquan
    Zheng, Guowan
    Ge, Minghua
    Ge, Jingyan
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 239
  • [8] Targeted Protein Degraders- The Druggability Perspective
    Singh, Satinder
    Srivastava, Pratima
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 113 (03) : 539 - 554
  • [9] Targeted protein knockdown using small molecule degraders
    Raina, Kanak
    Crews, Craig M.
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2017, 39 : 46 - 53
  • [10] N-Heterocycle based Degraders (PROTACs) Manifesting Anticancer Efficacy: Recent Advances
    Banerjee, Suddhasatwa
    Sharma, Sachin
    Thakur, Amandeep
    Sachdeva, Ritika
    Sharma, Ram
    Nepali, Kunal
    Liou, Jing Ping
    CURRENT DRUG TARGETS, 2023, 24 (15) : 1184 - 1208